• Explore /
  • Poster
  • / A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.

A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.

Abstract Video & Slides Poster

Authors

Yohann Loriot

Yohann Loriot

Gustave Roussy, University Paris Saclay, Villejuif, France

Yohann Loriot , Arlene O. Siefker-Radtke , Terence W. Friedlander , Andrea Necchi , Alexander Z Wei , Srikala S. Sridhar , Benjamin Garmezy , Santiago Arroyo , Emma Gartside , Jie Liu , Carly Campbell , Justin Bader , Daniel P. Petrylak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT06225596

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS4619)

DOI

10.1200/JCO.2024.42.16_suppl.TPS4619

Abstract #

TPS4619

Poster Bd #

308a

Abstract Disclosures

Similar Posters

First Author: Terence W. Friedlander

First Author: Nataliya Mar

First Author: Matt D. Galsky

First Author: Michael Seth Weinfeld